Tenax Therapeutics (NASDAQ:TENX) Stock Rating Lowered by Evercore

Posted by Francis Steltz on Aug 11th, 2026

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) was downgraded by investment analysts at Evercore from an “outperform” rating to an “in-line” rating in a research report issued on Tuesday. They presently have a $5.00 price objective on the specialty pharmaceutical company’s stock. Evercore’s price objective would indicate a potential upside of 262.32% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Tuesday, June 30th. Piper Sandler increased their price target on Tenax Therapeutics from $20.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, June 12th. Chardan Capital reaffirmed a “buy” rating and set a $27.00 price target on shares of Tenax Therapeutics in a report on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $35.00 price objective on shares of Tenax Therapeutics in a research report on Wednesday, July 29th. Finally, William Blair lowered Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.62.

Check Out Our Latest Analysis on TENX

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $1.38 on Tuesday. Tenax Therapeutics has a 52-week low of $1.31 and a 52-week high of $19.40. The firm has a market capitalization of $51.64 million, a PE ratio of -0.93 and a beta of 0.93. The company’s fifty day moving average price is $13.58 and its two-hundred day moving average price is $13.38.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. Analysts predict that Tenax Therapeutics will post -1.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TENX. Virtu Financial LLC bought a new stake in shares of Tenax Therapeutics during the third quarter worth approximately $92,000. Letko Brosseau & Associates Inc. bought a new position in Tenax Therapeutics in the fourth quarter valued at approximately $130,000. Corient Private Wealth LLC acquired a new position in shares of Tenax Therapeutics in the 4th quarter valued at $151,000. Quadrature Capital Ltd bought a new position in shares of Tenax Therapeutics in the 4th quarter worth $252,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Tenax Therapeutics during the fourth quarter worth $273,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics News Roundup

Here are the key news stories impacting Tenax Therapeutics this week:

Positive Sentiment: TNX-103 produced a 49% greater reduction in NT-proBNP versus placebo and lowered right ventricular systolic pressure by 3.5 mmHg in the overall trial population. Patients with below-median baseline walking ability improved by 26.3 meters versus placebo, suggesting the therapy may benefit patients with more severe disease. Tenax Therapeutics Reports Mixed Topline Results from Phase 3 LEVEL Trial
Positive Sentiment: Tenax plans to request a Type C meeting with the FDA and seek consultation from European regulators to discuss an enriched development strategy focused on patients with greater disease burden. Full LEVEL results are scheduled for presentation at the ESC Congress from August 28–31, 2026. Tenax Therapeutics Announces Topline LEVEL Results
Neutral Sentiment: Tenax Therapeutics is expected to report quarterly earnings on Wednesday. The release could provide updates on cash resources, development spending and management’s plans following the LEVEL results. Tenax Therapeutics Expected to Announce Quarterly Earnings
Neutral Sentiment: Brokerages maintain an average “Moderate Buy” recommendation, but analyst opinions and price targets are likely to be reassessed after the failed primary endpoint. Tenax Therapeutics Given Moderate Buy Recommendation
Negative Sentiment: The LEVEL study did not show a statistically significant improvement in the primary endpoint, 6-minute walk distance, with a 3.5-meter treatment difference and a p-value of 0.63. The key secondary endpoint, Kansas City Cardiomyopathy Questionnaire symptom score, also was not met. These failures could delay approval, require additional research and increase financing risk for the development-stage company. Tenax Therapeutics Heart Drug Misses Main Goal

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.